|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus显示文摘 | Alexander J. Thompson Andrew J. Muir Mark S. Sulkowski Dongliang Ge Jacques Fellay Kevin V. Shianna Thomas Urban Nezam H. Afdhal Ira M. Jacobson Rafael Esteban Fred Poordad Eric J. Lawitz Jonathan McCone Mitchell L. Shiffman Greg W. Galler William M. Lee | 2010 | Gastroenterology2010，，1： | 7 |
| 2 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial显示文摘 | Eric Lawitz Fred F Poordad Phillip S Pang Robert H Hyland Xiao Ding Hongmei Mo William T Symonds John G McHutchison Fernando E Membreno | 2013 | The Lancet2013，，： | 5 |
| 3 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 4 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 5 | Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy显示文摘 | Nezam H. Afdhal Geoffrey M. Dusheiko Edoardo G. Giannini Pei–Jer Chen Kwang–Hyub Han Aftab Mohsin Maribel Rodriguez–Torres Sorin Rugina Igor Bakulin Eric Lawitz Mitchell L. Shiffman Ghias–Un–Nabi Tayyab Fred Poordad Yasser Mostafa Kamel Andres Brainsky Ja | 2014 | Gastroenterology2014，，2： | 2 |
| 6 | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients显示文摘BACKGROUND The hepatitis C virus(HCV) NS5A inhibitor ABT-267(ombitasvir, OBV), the HCV NS4/4A protease inhibitor ABT-450(paritaprevir, PTV), the CYP3A inhibitor ritonavir(r) and the non-nucleoside NS5B polymerase inhibitor ABT-333(dasabuvir, DSV)(OBV/PTV/r + DSV) with or without ribavirin(RBV) is a direct-acting antiviral regimen approved in the United States and other major countries for the treatment of HCV in genotype 1(GT1) infected patients. Patients with HCV who are considered 'hard-to-cure' have generally been excluded from registration trials due to rigorous study inclusion criteria, presence of comorbidities and previous treatment failures.AIM To investigate the efficacy of this regimen in HCV G1-infected patients historically excluded from clinical trials.METHODS Patients were ≥ 18 years old and chronically infected with HCV GT1(GT1a, GT1b or GT1a/1b). Patients were treatment-na?ve or previously failed a regimen including pegylated interferon/RBV +/-telaprevir, boceprevir, or simeprevir.One hundred patients were treated with the study drug regimen, which was administered for 12 or 24 wk +/-RBV according to GT1 subtype and presence/absence of cirrhosis. Patients were evaluated every 4 wk from treatment day 1 and at 4 and 12 wk after end-of-treatment.RESULTS Many of the patients studied had comorbidities(44.2% hypertensive, 33.7%obese, 20.2% cirrhotic) and 16% previously failed HCV treatment. Ninety-six patients completed study follow-up and 99% achieved 12-wk sustained virologic response. The majority(88.4%) of patients had undetectable HCV RNA by week 4. The most common adverse events were fatigue(12%), headache(10%),insomnia(9%) and diarrhea(8%); none led to treatment discontinuation. Physical and mental patient reported outcomes scores significantly improved after treatment. Almost all(98%) patients were treatment compliant.CONCLUSION In an all-comers HCV GT1 population, 12 or 24-wk of OBV/PTV/r + DSV +/-RBV is highly effective and tolerable and results in better mental and physical health following treatment. | Nicole Loo Eric Lawitz Naim Alkhouri Jennifer Wells Carmen Landaverde Angie Coste Rossalynn Salcido Michael Scott Fred Poordad | 2019 | World Journal of Gastroenterology2019，25，18： | 2 |
| 7 | Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response显示文摘 | John M. Vierling Mitchell Davis Steven Flamm Stuart C. Gordon Eric Lawitz Eric M. Yoshida Joseph Galati Velimir Luketic Jonathan McCone Ira Jacobson Patrick Marcellin Andrew J. Muir Fred Poordad Lisa D. Pedicone Janice Albrecht Clifford Brass Anita Y.M. H | 2013 | Journal of Hepatology2013，，： | 2 |
| 8 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 2 |
| 9 | Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885显示文摘 | Kelly A. Wong Angela Worth Ross Martin Evguenia Svarovskaia Diana M. Brainard Eric Lawitz Michael D. Miller Hongmei Mo | 2013 | Antimicrobial Agents and Chemotherapy2013，，12： | 2 |
| 10 | A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment显示文摘 | Eric Lawitz Maribel Rodriguez-Torres Albrecht Stoehr Edward J. Gane Lawrence Serfaty Sanhita Bhanja Richard J. Barnard Di An Jacqueline Gress Peggy Hwang Niloufar Mobashery | 2013 | Journal of Hepatology2013，，1： | 1 |
| 11 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 1 |
| 12 | Next-Generation Regimens显示文摘 | John Vizuete Hope Hubbard Eric Lawitz | 2015 | Clinics in Liver Disease2015，，4： | 1 |
| 13 | Sustained virologic response rates with telaprevir by response after 4<ce:hsp sp='0.25'/>weeks of lead-in therapy in patients with prior treatment failure显示文摘 | Graham R. Foster Stefan Zeuzem Pietro Andreone Stanislas Pol Eric J. Lawitz Moises Diago Stuart Roberts Paul J. Pockros Zobair Younossi Isabelle Lonjon-Domanec Sandra De Meyer Don Luo Shelley George Maria Beumont Gaston Picchio | 2012 | Journal of Hepatology2012，，： | 1 |
| 14 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 1 |
| 15 | Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis显示文摘 | Maribel Rodriguez–Torres Albrecht Stoehr Edward J. Gane Lawrence Serfaty Eric Lawitz Amy Zhou Michael Bourque Sanhita Bhanja Julie Strizki Richard J.O. Barnard Peggy M.T. Hwang Mark J. DiNubile Niloufar Mobashery | 2014 | Clinical Gastroenterology and Hepatology2014，，： | 1 |
| 16 | The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors显示文摘 | Fernando E. Membreno Eric J. Lawitz | 2011 | Clinics in Liver Disease2011，，3： | 1 |
| 17 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 1 |
| 18 | Effects of Sofosbuvir-based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C显示文摘 | Zobair M. Younossi Maria Stepanova Linda Henry Edward Gane Ira M. Jacobson Eric Lawitz David Nelson Lynn Gerber Fatema Nader Sharon Hunt | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 19 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1‐infected treatment‐naive patients显示文摘 | Gregory T. Everson Karen D. Sims Paul J. Thuluvath Eric Lawitz Tarek Hassanein Maribel Rodriguez‐Torres Tadesse Desta Trevor Hawkins James M. Levin Federico Hinestrosa Vinod Rustgi Howard Schwartz Zobair Younossi Lynn Webster Norman Gitlin Timothy Eley Sh | 2016 | Liver Int2016，，2： | 1 |
| 20 | All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐na?ve patients with genotype 1 HCV infection显示文摘 | David L. Wyles Maribel Rodriguez‐Torres Eric Lawitz Mitchell L. Shiffman Stanislas Pol Robert W. Herring Benedetta Massetto Bittoo Kanwar James D. Trenkle Phil S. Pang Yanni Zhu Hongmei Mo Diana M. Brainard G. Mani Subramanian John G. McHutchison Fran?ois | 2014 | Hepatology2014，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员